# Orforglipron: what the GLP-1 pill is, and what the evidence shows

> Orforglipron (Foundayo) is a once-daily oral non-peptide GLP-1, FDA-approved April 2026. What the ATTAIN phase-3 trials show and how a pill differs from shots.

**Evidence grade:** Supported but limited (rung 2 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-06-30 · **Source page:** https://thepeptideera.com/evidence/orforglipron-glp1-pill

## Short answer
Orforglipron (brand name Foundayo) is a once-daily oral non-peptide GLP-1 receptor agonist that the FDA approved on April 1, 2026 for weight management in adults with obesity, or overweight with a related condition. In its phase-3 ATTAIN trials, the highest studied dose produced roughly 11–12% average weight loss over 72 weeks versus about 2% on placebo.

## Safety essentials worth knowing

These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority.

- **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician.
- **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception.
- **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
- **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment.
- **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician.
- **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery).

Orforglipron (brand name **Foundayo**) is a once-daily **oral, non-peptide GLP-1 receptor agonist** — a small molecule that activates the same appetite-and-glucose receptor as the injectable GLP-1 medicines, but in a tablet. The U.S. FDA approved it on **April 1, 2026** for weight management in adults with obesity, or with overweight plus at least one weight-related condition.

This page describes what the molecule is, what its approval and trials actually show, and how an oral GLP-1 differs from the injections. It contains **no doses**. It describes evidence; it does not give individual medical advice.

## What is orforglipron?

Orforglipron is a **small-molecule (non-peptide) GLP-1 receptor agonist** taken by mouth once a day. "Non-peptide" is the key engineering point: older GLP-1 drugs are peptides that the gut breaks down, which is why most are injected and why the one earlier oral GLP-1 peptide (oral semaglutide, sold as Rybelsus) must be taken on an empty stomach with strict food-and-water rules. Because orforglipron is a chemically different small molecule, its label states it **can be taken any time of day, with or without food or water** — a practical distinction for daily life. It is sold under the brand name Foundayo and made by Eli Lilly.

## Is orforglipron FDA-approved? What is it approved for?

Yes. On **April 1, 2026**, the FDA approved orforglipron (Foundayo) for **chronic weight management** — used with a reduced-calorie diet and increased physical activity — in adults with obesity, or adults with overweight who also have at least one weight-related condition such as high blood pressure or type 2 diabetes. It was the first new molecular entity cleared under the FDA's National Priority Voucher program. With approval, orforglipron moves onto the top of the Evidence Ladder for its **approved weight-management use** (an approved drug used as approved). The grade on this page stays at **supported-but-limited** for a deliberate reason: the human evidence is real and from large randomized trials, but it is **recent and narrow** — roughly 72-week trials, no published long-term cardiovascular-outcome results yet, and limited real-world or head-to-head data against the established injectables.

## What did the phase-3 trials show?

The approval rests on the **ATTAIN** phase-3 program. Two pivotal trials anchor the weight-loss evidence:

- **ATTAIN-1** (3,127 adults with obesity or overweight, *without* diabetes), published in the *New England Journal of Medicine* (2025). At 72 weeks the highest studied dose produced about **11–12% average body-weight loss** (the exact figure depends on the analysis method/estimand), versus about **2% on placebo**. Roughly **60% of people on the highest dose lost at least 10%** of their body weight.
- **ATTAIN-2** (adults with overweight or obesity *and* type 2 diabetes), published in *The Lancet* (2025). The highest dose produced about **10% average weight loss** at 72 weeks, alongside meaningful improvements in blood-sugar (HbA1c) measures.

Across both trials the **side-effect profile matched the GLP-1 class**: gastrointestinal events (nausea, diarrhea, vomiting, constipation) were the most common, mostly **mild to moderate**, and tended to cluster around dose increases. This is consistent, large-trial human evidence — the strong end of the ladder for what it directly measured.

## How does an oral GLP-1 differ from the injections?

The headline difference is **route and convenience**, not a proven advantage in long-term outcomes. A pill removes needles and the cold-chain storage that injectables need. But the injectable dual agonist tirzepatide (Zepbound/Mounjaro) and injectable semaglutide (Wegovy/Ozempic) have **larger and longer human track records**, including a published cardiovascular-outcome trial for semaglutide. Cross-trial weight-loss numbers are **not** a fair head-to-head; different trials, populations, and timeframes.

| | Orforglipron (Foundayo) | Oral semaglutide (Rybelsus) | Injectable GLP-1 / dual agonists (e.g. Wegovy, Zepbound) |
|---|---|---|---|
| Form | Once-daily **pill** | Once-daily pill | Once-weekly **injection** |
| Molecule type | Small molecule, **non-peptide** | Peptide | Peptide |
| Food/water rules | None per label | Strict empty-stomach + water + wait | Not applicable |
| Approved here for | Weight management (2026) | Type 2 diabetes (weight version varies by market) | Weight management and/or diabetes |
| Human track record | **Recent** (approved 2026) | Several years | Most extensive; CV-outcome data for semaglutide |
| Evidence grade (this site) | Supported-but-limited | Established (for its use) | Established |

## Does orforglipron carry a boxed warning?

Yes. Like other GLP-1 receptor agonists, the Foundayo label carries a **boxed warning about thyroid C-cell tumors**. The label notes orforglipron did not produce these tumors in rodents and the human relevance is undetermined — but it is **contraindicated** in people with a personal or family history of **medullary thyroid carcinoma** or **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)**. As with other GLP-1 medicines, the label also addresses risks such as pancreatitis and gallbladder disease. Read the full label and discuss your own history with a clinician.

## Frequently asked questions

**Is orforglipron the same as Ozempic or Wegovy in a pill?**
No. Those are semaglutide (a peptide). Orforglipron is a **different, non-peptide molecule**. It acts on the same GLP-1 receptor, but it is not "semaglutide in pill form."

**Is it approved for type 2 diabetes?**
The 2026 approval covered in this page is for **weight management**. Orforglipron has also been studied in type 2 diabetes (the ATTAIN-2 and separate diabetes trials), but check the current label for exactly which uses are approved where.

**How does its weight loss compare to the injections?**
In its own trials the highest dose averaged roughly **11–12%** at 72 weeks. That is substantial, but you **cannot** directly rank it against tirzepatide or semaglutide from separate trials — only head-to-head studies can do that fairly.

**Are the side effects different because it's a pill?**
The trial side-effect profile was the familiar GLP-1 pattern, **dominated by gastrointestinal symptoms** that were mostly mild-to-moderate and dose-related.

## Questions to ask a clinician

- Given my history and goals, is an oral GLP-1 a reasonable option, or is an injectable with a longer track record a better fit?
- Do I have any personal or family history (such as medullary thyroid cancer or MEN 2) that would rule this out?
- What is the plan for managing nausea or other GI symptoms in the early weeks?
- How will we monitor progress, and what would make us pause, change, or stop?
- If I could become pregnant: what should I know about contraception and timing before conceiving?

## Red flags / when to seek care

These are not "ride-it-out" symptoms — contact a clinician promptly, and seek urgent care for the severe versions:

- **Severe or persistent abdominal pain**, especially pain radiating to the back with repeated vomiting — a possible sign of **pancreatitis**.
- **Upper-right abdominal pain, fever, or yellowing of the skin or eyes** — possible **gallbladder disease**.
- **A swollen neck lump, hoarseness, or trouble swallowing** — report promptly given the thyroid warning.
- **Signs of dehydration** from prolonged vomiting or diarrhea — dizziness, very dark or scant urine, confusion.

If something feels genuinely wrong in your body, that is not a claim to grade on a ladder — it is a reason to call.

## Sources (7)
1. FDA Approves First New Molecular Entity Under National Priority Voucher Program (FDA press announcement, 2026) — https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program [NEWS]
2. FOUNDAYO (orforglipron) tablets — FDA Prescribing Information (2026) — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf [LABEL]
3. FOUNDAYO (orforglipron) — DailyMed label — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62 [LABEL]
4. Wharton, Aronne et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1, NEJM 2025;393:1796-1806) — https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 [RCT]
5. Orforglipron for obesity in people with type 2 diabetes (ATTAIN-2, The Lancet 2025) — https://doi.org/10.1016/S0140-6736(25)02165-8 [RCT]
6. A Study of Orforglipron (LY3502970) in Adults With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1, NCT05869903) — https://clinicaltrials.gov/study/NCT05869903 [REGISTRY]
7. FDA approves Lilly's Foundayo (orforglipron) — manufacturer announcement (2026) — https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html [NEWS]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.